Related Experiment Video
Updated: Nov 22, 2025

An Intact Pericardium Ischemic Rodent Model
Published on: September 2, 2021
Pericardial effusion in patients with COVID-19: case series
François Sauer1, Charlotte Dagrenat1, Philippe Couppie1
1Division of Cardiovascular Medicine, Centre Hospitalier de Haguenau, 64 Avenue du Professeur Leriche, Haguenau, Alsace 67500, France.
Insights
Three patients with COVID-19 developed pericarditis, with two also experiencing myocarditis. Early colchicine treatment led to rapid improvement, highlighting the need for increased cardiologist awareness of these cardiac complications.
Area of Science:
- Cardiology
- Infectious Diseases
- Cardiac Imaging
Background:
- The global spread of SARS-coronavirus-2 (COVID-19) has presented numerous public health challenges.
- Cardiac manifestations of COVID-19, including pericarditis and myocarditis, require further investigation.
Observation:
- Three adult patients (ages 51-84) presented with COVID-19-related pericarditis.
- Two patients also exhibited signs of myocarditis, with one case progressing to cardiac tamponade.
- Diagnostic methods included chest CT scans, SARS-CoV-2 swabs, and pericardial fluid PCR.
Findings:
- COVID-19 can lead to pericardial effusions, ranging from minimal to cardiac tamponade.
- Myopericarditis is a recognized complication of COVID-19 infection.
- Colchicine treatment demonstrated rapid clinical improvement in affected patients.
Implications:
- Cardiologists should maintain a high index of suspicion for COVID-19-related pericarditis and myopericarditis.
- Monitoring troponin kinetics and utilizing echocardiography can aid in early diagnosis.
- Prompt recognition and treatment of these cardiac conditions are crucial for patient outcomes.
Background:
SARS-coronavirus-2 [coronavirus disease 2019 (COVID-19)] infection is a public health issue affecting millions of people. It started in Wuhan in China in December 2019 spreading rapidly worldwide.
Case Summary:
Three patients aged 51-84 developed a pericarditis related to COVID-19, associated for two of them with a myocarditis. Case 1 was a COVID-19 cardiac tamponade without myocarditis, confirmed by a positive chest computed tomography (CT) scan. Case 2 showed a COVID-19 myopericarditis, confirmed by a positive chest CT scan and a SARS-coronavirus-2 positive swab. Case 3 was a cardiac tamponade due to COVID-19 pericarditis, with a positive polymerase chain reaction on pericardial fluid. They were all treated by colchicine and their condition improved rapidly.
Discussion:
Presumably rare, we reported three cases of pericardial effusions (PEs) occurring in a single cardiology centre. There is a higher incidence of COVID-19-related cardiac diseases such as pericarditis that can manifest as a minimal PE to a cardiac tamponade, which should result in a higher awareness of cardiologists. A systematic measure of the high-sensitivity troponin kinetic in patients affected by COVID-19 could be interesting in order to screen for potential myocarditis. Any unexplained haemodynamic failure or increased cardiac biomarkers should make the medical team search for myopericarditis by a transthoracic echocardiography.
More Related Videos
Related Concept Videos
Pericarditis II: Clinical Features and Diagnostic Tests
Pericarditis I: Introduction
Pericarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Pericarditis IV: Nursing Management
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:

